Want to see ECL full AI Analyst Report?
Revenue by Segment
Breaks down sales across various business areas, indicating which segments are performing well and contributing most to overall revenue growth.Ecolab’s segment mix is shifting: Institutional & Specialty is the clear, durable growth engine (continuing into 2026), while Industrial delivers steady, compounding revenue that underpins margin leverage. Healthcare & Life Sciences looks volatile and softened late‑2024, but management highlights rapid bioprocessing and Life Sciences acceleration that may not yet fully show in legacy reporting. Recent zeros likely reflect a reporting reclassification tied to OVIVO/CoolIT M&A; expect near‑term commodity headwinds offset by pricing/surcharge and H2 margin stabilization, with longer‑term upside from high‑margin digital and life‑sciences exposure.
Date | Other | Corporate | Industrial | Institutional and Specialty | Healthcare and Lifesciences |
|---|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $0.00 | $0.00 | $1.62B | $0.00 |
Mar 31, 2026 | $0.00 | $0.00 | $0.00 | $1.51B | $0.00 |
Dec 31, 2025 | $0.00 | $0.00 | $0.00 | $1.50B | $0.00 |
Sep 30, 2025 | $0.00 | $0.00 | $0.00 | $1.54B | $0.00 |
Jun 30, 2025 | $0.00 | $0.00 | $0.00 | $1.51B | $0.00 |
Mar 31, 2025 | $0.00 | $0.00 | $0.00 | $1.41B | $0.00 |
Dec 31, 2024 | $295.20M | $0.00 | $2.07B | $1.37B | $322.10M |
Sep 30, 2024 | $308.70M | $0.00 | $1.99B | $1.40B | $334.10M |
Jun 30, 2024 | $297.10M | $0.00 | $1.94B | $1.36B | $390.80M |
Mar 31, 2024 | $266.80M | $0.00 | $1.84B | $1.27B | $382.90M |